Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | POLB | P06746 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL837139 | 0.89 | ALDH1A1 (0.55) | ALDH1A1POLBMEN1KMT2ACYP2C19 | |
| SCHEMBL16897444 | 0.86 | CYP2C19 (0.57) | ALDH1A1POLBMEN1KMT2ACYP2C19 | |
| SCHEMBL1466916 | 0.86 | POLB (0.62) | ALDH1A1POLBMEN1KMT2ACYP2C19 | |
| SCHEMBL23164033 | 0.86 | ALDH1A1 (0.47) | ALDH1A1POLBMEN1KMT2ACYP2C19 | |
| SCHEMBL31525688 | 0.86 | ALDH1A1 (0.60) | ALDH1A1POLBMEN1KMT2ACYP2C19 | |
| SCHEMBL8586765 | 0.85 | KDM4E (0.58) | ALDH1A1MEN1KMT2ACYP2C19CYP3A4 | |
| SCHEMBL2701584 | 0.84 | ALDH1A1 (0.59) | ALDH1A1POLBMEN1KMT2ACYP2C19 | |
| SCHEMBL3904681 | 0.84 | HDAC1 (0.52) | ALDH1A1POLBMEN1KMT2ACYP2C19 | |
| SCHEMBL16477203 | 0.84 | ALDH1A1 (0.46) | ALDH1A1POLBMEN1KMT2ACYP2C19 | |
| SCHEMBL1121038 | 0.84 | HDAC1 (0.53) | ALDH1A1POLBMEN1KMT2ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | DOMAIN THERAPEUTICS (FR) | 2026-01-20 | — | — | US | disclosed |
| CN-117980293-A | Hydroxamic acid compound with ENPP1 inhibitory activity and application thereof | 上海海和药物研究开发股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-4038052-B1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2024-02-07 | — | — | EP | disclosed |
| US-20220378772-A1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2022-12-01 | — | — | US | disclosed |
| EP-4038052-A2 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | Domain Therapeutics (FR) | 2022-08-10 | — | — | EP | disclosed |
| CN-114555573-A | Prostaglandin E2(PGE2)EP4Receptor antagonists | 多曼治疗学公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021064189-A2 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | PTGER1, PTGER4, PTGER3 | ALDH1A1 687/4885POLB 2895/4885MEN1 3795/4885 |
| US-20220378772-A1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER2 | ALDH1A1 950/4885POLB 2958/4885MEN1 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.